CJC-1295 (no DAC) vs MK-677
Both CJC-1295 (no DAC) and MK-677 are used for growth-hormone and anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | MK-677 |
|---|---|---|
| Evidence Grade | B | B+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — investigational (orally active GH secretagogue) |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 10–25 mg orally, once daily |
| Clinics Indexed | 156 | 165 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone, anti-aging |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.